huCART19-IL18-eDHFR Cells in Relapsed/Refractory Follicular Lymphoma

This is a phase 1, open-label study to evaluate the feasibility, safety and preliminary efficacy of huCART19-IL18-eDHFR cells administered in patients with relapsed or refractory follicular lymphoma. This study will be initiated as a single arm study (Treatment Arm A), which will evaluate the use of huCART19-IL18-eDHFR cells without prior lymphodepletion. In this Treatment Arm A, all subjects will receive a single flat dose of 7x10\[6\] huCART19-IL18-eDHFR cells (Dose Level 1; DL1). Additional treatment arms may also be introduced in the future, via subsequent amendment(s). Co-expression of e

Trial Details

NCT ID
NCT07343934
Phase
PHASE1
Sponsor
University of Pennsylvania
Status
RECRUITING
Cancer Type
Lymphoma
Interventions
  • huCART19-IL18-eDHFR cells
  • [18F]Fluoropropyl-Trimethoprim
Locations (sample)
  • Philadelphia, Pennsylvania, United States|39.95238,-75.16362

Key Eligibility Criteria

  • Signed informed consent form
  • Male or females age ≥ 18 years
  • Diagnosis of follicular lymphoma, grades 1-3A
  • Relapsed or refractory disease after at least 2 prior lines of systemic therapy as follows:

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lymphoma Trials on Trialify →